Cargando…
Is insulin an endogenous cardioprotector?
Stress hyperglycemia and diabetes mellitus with myocardial infarction are associated with increased risk for in-hospital mortality, congestive heart failure, or cardiogenic shock. Hyperglycemia triggers free radical generation and suppresses endothelial nitric oxide generation, and thus initiates an...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137317/ https://www.ncbi.nlm.nih.gov/pubmed/12398773 |
_version_ | 1782120430366097408 |
---|---|
author | Das, Undurti N |
author_facet | Das, Undurti N |
author_sort | Das, Undurti N |
collection | PubMed |
description | Stress hyperglycemia and diabetes mellitus with myocardial infarction are associated with increased risk for in-hospital mortality, congestive heart failure, or cardiogenic shock. Hyperglycemia triggers free radical generation and suppresses endothelial nitric oxide generation, and thus initiates and perpetuates inflammation. Conversely, insulin suppresses production of tumor necrosis factor-α and free radicals, enhances endothelial nitric oxide generation, and improves myocardial function. It is proposed that the balance between insulin and plasma glucose levels is critical to recovery and/or complications that occur following acute myocardial infarction and in the critically ill. Adequate attention should be given to maintaining euglycemia (plasma glucose ≤ 110 mg/dl) in order to reduce infarct size and improve cardiac function while using a glucose–insulin–potassium cocktail. |
format | Text |
id | pubmed-137317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1373172003-02-27 Is insulin an endogenous cardioprotector? Das, Undurti N Crit Care Commentary Stress hyperglycemia and diabetes mellitus with myocardial infarction are associated with increased risk for in-hospital mortality, congestive heart failure, or cardiogenic shock. Hyperglycemia triggers free radical generation and suppresses endothelial nitric oxide generation, and thus initiates and perpetuates inflammation. Conversely, insulin suppresses production of tumor necrosis factor-α and free radicals, enhances endothelial nitric oxide generation, and improves myocardial function. It is proposed that the balance between insulin and plasma glucose levels is critical to recovery and/or complications that occur following acute myocardial infarction and in the critically ill. Adequate attention should be given to maintaining euglycemia (plasma glucose ≤ 110 mg/dl) in order to reduce infarct size and improve cardiac function while using a glucose–insulin–potassium cocktail. BioMed Central 2002 2002-07-31 /pmc/articles/PMC137317/ /pubmed/12398773 Text en Copyright © 2002 BioMed Central Ltd |
spellingShingle | Commentary Das, Undurti N Is insulin an endogenous cardioprotector? |
title | Is insulin an endogenous cardioprotector? |
title_full | Is insulin an endogenous cardioprotector? |
title_fullStr | Is insulin an endogenous cardioprotector? |
title_full_unstemmed | Is insulin an endogenous cardioprotector? |
title_short | Is insulin an endogenous cardioprotector? |
title_sort | is insulin an endogenous cardioprotector? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137317/ https://www.ncbi.nlm.nih.gov/pubmed/12398773 |
work_keys_str_mv | AT dasundurtin isinsulinanendogenouscardioprotector |